Non-Current Assets

Goodwill

Royalty Pharma Goodwill remained flat by 0.0% to $924.63M in Q1 2026 compared to the prior quarter.

Analysis

StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ4 2014
Last reportedQ1 2026

How to read this metric

A significant increase indicates recent M&A activity, while a sudden decrease typically signals an impairment charge due to underperforming acquisitions.

Detailed definition

Goodwill represents the premium paid over the fair market value of net identifiable assets during an acquisition. It ref...

Peer comparison

Standard metric for companies that grow through acquisition; comparable across all industries.

Metric ID: goodwill

Historical Data

5 periods
 Q4 '24Q2 '25Q3 '25Q4 '25Q1 '26
Value$0.00$924.63M$924.63M$924.63M$924.63M
QoQ Change——+0.0%+0.0%+0.0%
Range$0.00 – $924.63M
Current Streak3+ quarters growth

Goodwill at Other Companies

Viatris logo
ViatrisVTRSView metric
Biogen logo
BiogenBIIBView metric
Pfizer logo
PfizerPFEView metric
AbbVie logo
AbbVieABBVView metric
Amgen logo
AmgenAMGNView metric
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTXView metric

Frequently Asked Questions

What is Royalty Pharma's goodwill?
Royalty Pharma (RPRX) reported goodwill of $924.63M in Q1 2026.
What does goodwill mean?
The excess price paid for an acquisition over the fair value of its net assets.